Axsome: The Alzheimer's Agitation Program For AXS-05
Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions.
Adaptimmune Therapeutics (ADAP) Receives a Buy from Mizuho Securities
In a report released yesterday, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research ...
Lazard US Equity Concentrated Portfolio Q4 2024 Commentary
In Q4 2024, the Lazard US Equity Concentrated Portfolio underperformed its benchmark. Click here to read the full commentary.
Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insmed (INSM) Gets a Buy from Mizuho Securities
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Insmed ( INSM – Research Report) today and set a price target of $96.00. The company’s shares closed yesterday at $76.99.
Axsome Therapeutics management to meet with Truist
Meeting to be held in New York on March 18 at 6 pm hosted by Truist. Light Up your Portfolio with Spark:Easily identify stocks' risks and ...
Charles Schwab Investment Management Inc. Increases Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Charles Schwab Investment Management Inc. raised its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free ...
Harmony Biosciences Holdings (HRMY) Receives a Buy from Mizuho Securities
Detailed price information for Harmony Biosciences Holdings Inc (HRMY-Q) from The Globe and Mail including charting and trades.